Monitoring adiponectin in these contexts may be particularly valuable in depression subtypes with metabolic comorbidities, such as insulin resistance or obesity, where identifying a distinct “metabotype” could guide more personalized and integrative therapeutic approaches. Here, ADIPOQ is linked to depressive symptom measurement.